MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

Penumbra Inc

Slēgts

SektorsVeselības aprūpe

320 -0.77

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

309.45

Max

323.22

Galvenie mērījumi

By Trading Economics

Ienākumi

581K

46M

Pārdošana

15M

355M

P/E

Sektora vidējais

75.179

87.826

Peļņas marža

12.927

Darbinieki

4,500

EBITDA

4M

55M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+9.22% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 17. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

3.5B

12B

Iepriekšējā atvēršanas cena

320.77

Iepriekšējā slēgšanas cena

320

Ziņu noskaņojums

By Acuity

50%

50%

173 / 370 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Penumbra Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. janv. 23:54 UTC

Tirgus saruna

CBA Could Underperform Again in 2026 -- Market Talk

2026. g. 12. janv. 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 12. janv. 23:48 UTC

Tirgus saruna

Nikkei May Rise on Weaker Yen -- Market Talk

2026. g. 12. janv. 23:43 UTC

Tirgus saruna

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026. g. 12. janv. 23:18 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

2026. g. 12. janv. 21:56 UTC

Tirgus saruna

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

2026. g. 12. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 12. janv. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 12. janv. 21:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 12. janv. 21:18 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 12. janv. 21:18 UTC

Tirgus saruna

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

2026. g. 12. janv. 20:54 UTC

Peļņas

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

2026. g. 12. janv. 20:48 UTC

Tirgus saruna

Oil Futures Settle Higher in Choppy Trade -- Market Talk

2026. g. 12. janv. 20:33 UTC

Tirgus saruna

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

2026. g. 12. janv. 20:18 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

2026. g. 12. janv. 20:18 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

2026. g. 12. janv. 19:39 UTC

Tirgus saruna

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

2026. g. 12. janv. 19:36 UTC

Tirgus saruna

Gold and Silver Set New Records on Fed Probe -- Market Talk

2026. g. 12. janv. 19:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 12. janv. 19:33 UTC

Tirgus saruna

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

2026. g. 12. janv. 19:24 UTC

Iegādes, apvienošanās, pārņemšana

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

2026. g. 12. janv. 19:22 UTC

Iegādes, apvienošanās, pārņemšana

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

2026. g. 12. janv. 18:21 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

2026. g. 12. janv. 18:20 UTC

Iegādes, apvienošanās, pārņemšana

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

2026. g. 12. janv. 18:19 UTC

Tirgus saruna

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

2026. g. 12. janv. 18:16 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

2026. g. 12. janv. 18:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 12. janv. 18:09 UTC

Tirgus saruna

Baidu's Outlook Bodes Well For Shares -- Market Talk

2026. g. 12. janv. 18:01 UTC

Iegādes, apvienošanās, pārņemšana

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

2026. g. 12. janv. 18:00 UTC

Tirgus saruna

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Salīdzinājums

Cenas izmaiņa

Penumbra Inc Prognoze

Cenas mērķis

By TipRanks

9.22% augšup

Prognoze 12 mēnešiem

Vidējais 344.64 USD  9.22%

Augstākais 388 USD

Zemākais 266 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Penumbra Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

15 ratings

14

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

288.28 / 292.9394Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bullish Evidence

Noskaņojums

By Acuity

173 / 370 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat